Aeterna Zentaris Inc. (NASDAQ:AEZS)’s share price was up 2.8% on Friday . The company traded as high as $3.74 and last traded at $3.72, with a volume of 68,277 shares changing hands. The stock had previously closed at $3.62.

Several equities research analysts have commented on AEZS shares. Canaccord Genuity restated a “buy” rating and set a $9.00 target price on shares of Aeterna Zentaris in a research report on Tuesday. Zacks Investment Research upgraded shares of Aeterna Zentaris from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a research report on Monday, August 15th. Maxim Group restated a “buy” rating and set a $11.00 target price on shares of Aeterna Zentaris in a research report on Saturday, August 13th. Finally, HC Wainwright restated a “buy” rating on shares of Aeterna Zentaris in a research report on Thursday, August 11th.

The stock’s market capitalization is $36.97 million. The stock has a 50-day moving average of $3.51 and a 200-day moving average of $3.51.

Aeterna Zentaris (NASDAQ:AEZS) last posted its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.82) by $0.11. On average, analysts forecast that Aeterna Zentaris Inc. will post ($2.61) earnings per share for the current fiscal year.

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.